SVN-SDN-14 PTSD Programme - Positive pre-clinical results with three high-performing candidates advancing to in vivo studies Biotech Investing
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA Life Science Investing
Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights Life Science Investing
Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025 Life Science Investing
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET Life Science Investing
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032 Life Science Investing
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression Life Science Investing
